Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Equity Average (2016 - 2025)

Historic Equity Average for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $18.7 million.

  • Aytu Biopharma's Equity Average fell 3832.09% to $18.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.7 million, marking a year-over-year decrease of 3832.09%. This contributed to the annual value of $23.3 million for FY2025, which is 3040.12% down from last year.
  • Per Aytu Biopharma's latest filing, its Equity Average stood at $18.7 million for Q4 2025, which was down 3832.09% from $21.1 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Equity Average high stood at $140.4 million for Q2 2021, and its period low was $18.7 million during Q4 2025.
  • In the last 5 years, Aytu Biopharma's Equity Average had a median value of $37.9 million in 2023 and averaged $55.1 million.
  • As far as peak fluctuations go, Aytu Biopharma's Equity Average skyrocketed by 3385.14% in 2021, and later crashed by 6279.89% in 2022.
  • Aytu Biopharma's Equity Average (Quarter) stood at $108.5 million in 2021, then tumbled by 56.61% to $47.1 million in 2022, then tumbled by 30.95% to $32.5 million in 2023, then decreased by 6.81% to $30.3 million in 2024, then crashed by 38.32% to $18.7 million in 2025.
  • Its Equity Average stands at $18.7 million for Q4 2025, versus $21.1 million for Q3 2025 and $26.9 million for Q2 2025.